Strides receives regulatory nod for its skin disease drug
12 June 2014 | News | By BioSpectrum Bureau
Strides receives regulatory nod for its skin disease drug
Strides Arcolab has received regulatory approval for its skin disease drug
Bangalore-based Strides Arcolab has received regulatory approval for its skin disease drug Methoxsalen. The drug is available in capsules of 10 mg. The USFDA approval will mean that the capsules can now be sold in the US.
"The US market for generic Methoxsalen capsules is pegged at about $13.6 million, with no other generic player in the same market," the company said, citing IMS data.
"The product will be manufactured at the company's FDA-approved oral dosage facility in Bangalore and marketed directly by Strides in the US," they added further.
Methoxsalen is used to treat psoriasis, eczema, vitiligo and some cutaneous lymphomas in conjunction with exposing the skin to UVA light from lamps or sunlight.
It modifies the way skin cells receive UVA radiation, clearing up the disease.
